KAN.ST
Price:
$1.46
Market Cap:
$176.93M
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
Industry
Biotechnology
IPO Date
2011-02-25
Stock Exchange
STO
Ticker
KAN.ST
According to Kancera AB (publ)’s latest financial reports and current stock price. The company's current ROE is -66.81%. This represents a change of 280.87% compared to the average of -17.54% of the last 4 quarters.
The mean historical ROE of Kancera AB (publ) over the last ten years is -97.69%. The current -66.81% ROE has changed -31.61% with respect to the historical average. Over the past ten years (40 quarters), KAN.ST's ROE was at its highest in in the June 2016 quarter at -7.70%. The ROE was at its lowest in in the June 2019 quarter at -66.74%.
Average
-97.69%
Median
-80.49%
Minimum
-207.22%
Maximum
-37.28%
Discovering the peaks and valleys of Kancera AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 287.37%
Maximum Annual ROE = -37.28%
Minimum Annual Increase = -68.25%
Minimum Annual ROE = -207.22%
Year | ROE | Change |
---|---|---|
2024 | -71.53% | -47.45% |
2023 | -136.14% | 177.31% |
2022 | -49.09% | 31.67% |
2021 | -37.28% | -43.33% |
2020 | -65.79% | -68.25% |
2019 | -207.22% | 50.48% |
2018 | -137.71% | -5.14% |
2017 | -145.17% | 287.37% |
2016 | -37.48% | -58.10% |
2015 | -89.45% | 52.76% |
The current ROE of Kancera AB (publ) (KAN.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-85.59%
5-year avg
-71.97%
10-year avg
-97.69%
Kancera AB (publ)’s ROE is greater than CombiGene AB (publ) (-50.67%), greater than Cantargia AB (publ) (-166.31%), greater than Fingerprint Cards AB (publ) (-158.71%), less than SpectrumOne AB (publ) (57.75%), greater than BioInvent International AB (publ) (-49.84%),
Company | ROE | Market cap |
---|---|---|
-50.67% | $48.91M | |
-166.31% | $281.93M | |
-158.71% | $150.12M | |
57.75% | $92.06M | |
-49.84% | $2.34B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kancera AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kancera AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Kancera AB (publ)'s ROE?
How is the ROE calculated for Kancera AB (publ) (KAN.ST)?
What is the highest ROE for Kancera AB (publ) (KAN.ST)?
What is the 3-year average ROE for Kancera AB (publ) (KAN.ST)?
What is the 5-year average ROE for Kancera AB (publ) (KAN.ST)?
How does the current ROE for Kancera AB (publ) (KAN.ST) compare to its historical average?